Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada
| Autor: | Fannie Defay, Brigitte Lefebvre, Philippe De Wals, Monique Landry, Geneviève Deceuninck, Monique Douville-Fradet |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Serotype medicine.medical_specialty Pediatrics Heptavalent Pneumococcal Conjugate Vaccine Pneumococcal disease Reference laboratory complex mixtures Pneumococcal Infections Pneumococcal conjugate vaccine Herd immunity Pneumococcal Vaccines Young Adult Environmental health medicine Humans Registries Serotyping Disease Notification Immunization Schedule Aged Aged 80 and over Vaccines Conjugate General Veterinary General Immunology and Microbiology Immunization Programs business.industry Incidence Incidence (epidemiology) Public health Infant Newborn Quebec Public Health Environmental and Occupational Health Infant Middle Aged High uptake Streptococcus pneumoniae Infectious Diseases Child Preschool Molecular Medicine business medicine.drug |
| Zdroj: | Vaccine. 32:1501-1506 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2013.11.028 |
| Popis: | Quebec was the first jurisdiction in the world to recommend a 3-dose (2+1) pneumococcal conjugate vaccine (PCV) schedule. The program was implemented in December 2004 with a catch-up for children5 years. PCV-7 was first used and replaced, respectively, by PCV-10 in 2009 and by PCV-13 in 2011.Cases of invasive pneumococcal disease (IPD) notified to public health authorities and isolates submitted to the provincial reference laboratory during the period 2000-2011 were analyzed.IPD incidence in children5 years was 67/100,000 in 2001-2004, and decreased to 32/100,000 in 2007-2009 following PCV-7 implementation (p0.01). A further decrease to 24/100,000 was observed in 2010-2011 following PCV-10 introduction (p0.01). PCV-7 serotypes represented 82% of the total IPD cases in 2000-2004 and elimination was achieved in 2011. Main emerging serotypes were 19A and 7F. Children exposed to the PCV-10 experienced lower IPD rates and all serotypes contributed to the decline, mainly 7F and 19A. In adults, a decrease of low magnitude was observed in 2005-2006 but rates in 2007-2009 were higher than in the prevaccination period.A 3-dose PCV schedule with high uptake is highly effective and should be recommended worldwide. Serotype replacement eroded benefits especially in adults. PCV-10 introduction had an effect and the impact of PCV-13 use remains to be evaluated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect